186 related articles for article (PubMed ID: 23485871)
1. Physiological characterization of a mouse model of cachexia in colorectal liver metastases.
Murphy KT; Struk A; Malcontenti-Wilson C; Christophi C; Lynch GS
Am J Physiol Regul Integr Comp Physiol; 2013 May; 304(10):R854-64. PubMed ID: 23485871
[TBL] [Abstract][Full Text] [Related]
2. MC38 Tumors Induce Musculoskeletal Defects in Colorectal Cancer.
Huot JR; Pin F; Essex AL; Bonetto A
Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33540821
[TBL] [Abstract][Full Text] [Related]
3. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice.
Murphy KT; Chee A; Gleeson BG; Naim T; Swiderski K; Koopman R; Lynch GS
Am J Physiol Regul Integr Comp Physiol; 2011 Sep; 301(3):R716-26. PubMed ID: 21677277
[TBL] [Abstract][Full Text] [Related]
4. HCT116 colorectal liver metastases exacerbate muscle wasting in a mouse model for the study of colorectal cancer cachexia.
Huot JR; Novinger LJ; Pin F; Bonetto A
Dis Model Mech; 2020 Jan; 13(1):. PubMed ID: 31915140
[TBL] [Abstract][Full Text] [Related]
5. Importance of functional and metabolic impairments in the characterization of the C-26 murine model of cancer cachexia.
Murphy KT; Chee A; Trieu J; Naim T; Lynch GS
Dis Model Mech; 2012 Jul; 5(4):533-45. PubMed ID: 22563056
[TBL] [Abstract][Full Text] [Related]
6. Formation of colorectal liver metastases induces musculoskeletal and metabolic abnormalities consistent with exacerbated cachexia.
Huot JR; Novinger LJ; Pin F; Narasimhan A; Zimmers TA; O'Connell TM; Bonetto A
JCI Insight; 2020 May; 5(9):. PubMed ID: 32298240
[TBL] [Abstract][Full Text] [Related]
7. Cancer cachexia decreases specific force and accelerates fatigue in limb muscle.
Roberts BM; Frye GS; Ahn B; Ferreira LF; Judge AR
Biochem Biophys Res Commun; 2013 Jun; 435(3):488-92. PubMed ID: 23673294
[TBL] [Abstract][Full Text] [Related]
8. ACVR2B antagonism as a countermeasure to multi-organ perturbations in metastatic colorectal cancer cachexia.
Huot JR; Pin F; Narasimhan A; Novinger LJ; Keith AS; Zimmers TA; Willis MS; Bonetto A
J Cachexia Sarcopenia Muscle; 2020 Dec; 11(6):1779-1798. PubMed ID: 33200567
[TBL] [Abstract][Full Text] [Related]
9. Sex differences in skeletal muscle alterations in a model of colorectal cancer.
Greenman AC; Albrecht DM; Halberg RB; Diffee GM
Physiol Rep; 2020 Mar; 8(5):e14391. PubMed ID: 32170841
[TBL] [Abstract][Full Text] [Related]
10. Impaired Muscle Regeneration in Cancer-Associated Cachexia.
Arneson PC; Doles JD
Trends Cancer; 2019 Oct; 5(10):579-582. PubMed ID: 31706505
[TBL] [Abstract][Full Text] [Related]
11. Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved?
Penna F; Bonetto A; Muscaritoli M; Costamagna D; Minero VG; Bonelli G; Rossi Fanelli F; Baccino FM; Costelli P
Int J Cancer; 2010 Oct; 127(7):1706-17. PubMed ID: 20039316
[TBL] [Abstract][Full Text] [Related]
12. Targeting interleukin-1 for reversing fat browning and muscle wasting in infantile nephropathic cystinosis.
Cheung WW; Hao S; Zheng R; Wang Z; Gonzalez A; Zhou P; Hoffman HM; Mak RH
J Cachexia Sarcopenia Muscle; 2021 Oct; 12(5):1296-1311. PubMed ID: 34196133
[TBL] [Abstract][Full Text] [Related]
13. Molecular and Physiological Evaluation of Pancreatic Cancer-Induced Cachexia.
Shukla SK; Dasgupta A; Mulder SE; Singh PK
Methods Mol Biol; 2019; 1882():321-333. PubMed ID: 30378066
[TBL] [Abstract][Full Text] [Related]
14. Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse.
Aulino P; Berardi E; Cardillo VM; Rizzuto E; Perniconi B; Ramina C; Padula F; Spugnini EP; Baldi A; Faiola F; Adamo S; Coletti D
BMC Cancer; 2010 Jul; 10():363. PubMed ID: 20615237
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D repletion ameliorates adipose tissue browning and muscle wasting in infantile nephropathic cystinosis-associated cachexia.
Cheung WW; Hao S; Wang Z; Ding W; Zheng R; Gonzalez A; Zhan JY; Zhou P; Li S; Esparza MC; Hoffman HM; Lieber RL; Mak RH
J Cachexia Sarcopenia Muscle; 2020 Feb; 11(1):120-134. PubMed ID: 31721480
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial degeneration precedes the development of muscle atrophy in progression of cancer cachexia in tumour-bearing mice.
Brown JL; Rosa-Caldwell ME; Lee DE; Blackwell TA; Brown LA; Perry RA; Haynie WS; Hardee JP; Carson JA; Wiggs MP; Washington TA; Greene NP
J Cachexia Sarcopenia Muscle; 2017 Dec; 8(6):926-938. PubMed ID: 28845591
[TBL] [Abstract][Full Text] [Related]
17. Development of ovarian tumour causes significant loss of muscle and adipose tissue: a novel mouse model for cancer cachexia study.
Luan Y; Zhang Y; Yu SY; You M; Xu PC; Chung S; Kurita T; Zhu J; Kim SY
J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1289-1301. PubMed ID: 35044098
[TBL] [Abstract][Full Text] [Related]
18. Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia.
Ham DJ; Murphy KT; Chee A; Lynch GS; Koopman R
Clin Nutr; 2014 Jun; 33(3):448-58. PubMed ID: 23835111
[TBL] [Abstract][Full Text] [Related]
19. Advances in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions.
Siddiqui JA; Pothuraju R; Jain M; Batra SK; Nasser MW
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188359. PubMed ID: 32222610
[TBL] [Abstract][Full Text] [Related]
20. FoxP1 is a transcriptional repressor associated with cancer cachexia that induces skeletal muscle wasting and weakness.
Neyroud D; Nosacka RL; Callaway CS; Trevino JG; Hu H; Judge SM; Judge AR
J Cachexia Sarcopenia Muscle; 2021 Apr; 12(2):421-442. PubMed ID: 33527776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
